Online literature searches were performed via PubMed, PubMed Central, and Google using the keywords “immune checkpoint inhibition”; “host-directed therapy”; “T cell exhaustion”; “cancer immunotherapy”; “anti-PD-1 therapy”; “anti-PD-L1 therapy”; “chronic infections”; “antigen-specif...
While both combination therapies led to further increases in CD8+T-cells, only the lenvatinib and anti-PD-1 combination decreased PMN-MDSCs. PMN-MDSC expansion was also seen in the blood of mice and one patient receiving lenvatinib therapy for ATC. RNA-Seq of the ATC cell line used in ...
70.Genmab与BioNtech合作开发的PD-L1 x 4-1BB双抗试图克服第一代4-1BB激动剂的缺陷。它通过阻断PD-1:PD-L1轴以及有条件地刺激4-1BB来重新激活抗肿瘤免疫反应。该双抗Fc没有免疫功能,它的PD-L1特异性臂对PD-L1检查点的阻断有持续活性,但4-1BB...
1st-line anti-PD-1/PD-L1 therapy can be chosen as the best modality. Squamous cell lung cancer also benefit from anti-PD-1/PD-L1 therapy. 展开 关键词: PD-1 PD-L1 Non-small cell lung cancer Checkpoint inhibitor Meta-analysis DOI: 10.1007/s12253-015-0011-z ...
摘要: 程序性细胞死亡-1 (PD-1) 免疫检查点抑制剂在多种肿瘤中显示出良好的疗效。在这里,我们报告一个不可切除的局部进展期胃癌 (GC) 与程序性细胞死亡 ligand-1 (PD-L1) 阳性和微卫星不稳定 (MSI),作为一线治疗方案,单剂量的 anti-PD-1 联合化疗治疗后,病理完全缓解 (pCR) 表现出意想不到的疗效。一...
CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Immune checkpoint blockade with monoclonal antibodies directed at the inhibitory immune receptors CTLA-4, PD-1, and PD-L1 has emerged as a successful treat... PA Ott,FS Hodi,C...
Immunotherapy, especially anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) treatment has significantly improved the survival of non-small cell lung cancer (NSCLC) patients. However, the overall response rate remains unsati
The main challenges for programmed cell death 1(PD-1)/PD-1 ligand (PD-L1) checkpoint blockade lie in a lack of sufficient T cell infiltration, tumor immunosuppressive microenvironment, and the inadequate tumor accumulation and penetration of anti-PD-1/PD
PURPOSE: To better understand the efficacy and safety of anti-PD-1/PD-L1 therapy (atezolizumab, pembrolizumab, nivolumab) in patients with previously treated advanced non-small-cell lung cancer (NSCLC). METHODS: The Cochrane Controlled Trial Register, Embase, Medline, and the Science Citation Index...
Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types. An